Earlier this year, Veritas Pharma's subsidiary, Cannevert Therapeutics, signed an agreement with Puerto Rico's Fundacion de Investigacion clinical research to perform trials of its lead cannabis strain, CTL-X, to target pain. The anticipated approvals were expected to come at the end of the first quarter of 2018 with a potential start this Q2 2018. Challenges arose with the importation of placebo cannabis from a non-United States supplier. The designated placebo is a cannabis plant material which resembles C
Read more
Veritas Pharma subsidiary to start trials in Q3
